HTA225 A Review of External Evidence Used to Support Survival Extrapolation in Assessments of Cancer Drugs by the National Institute for Health and Care Excellence (NICE)

A Bullement,S Critchlow,Md Stevenson,G Baio,N Latimer

doi:10.1016/j.jval.2022.09.1683

HTA225 A Review of External Evidence Used to Support Survival Extrapolation in Assessments of Cancer Drugs by the National Institute for Health and Care Excellence (NICE)

A Bullement, S Critchlow + Show 3 more

Open Access

https://doi.org/10.1016/j.jval.2022.09.1683

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Dec 1, 2022
License type: publisher-specific-oa

Affiliation: University of Sheffield, University College London

#National Institute For Health And Care Excellence #External Evidence + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

External evidence is often used in health technology assessment (HTA) submissions to NICE to supplement data available from the pivotal clinical trial programme when performing survival extrapolation; however, there is no published guidance (including from NICE) regarding how this should be done. This study aimed to investigate how external evidence has been used in recent appraisals of cancer drugs conducted by NICE to aid extrapolation of survival outcomes.

Full Text